Skip to main navigation

Investor Relations

April 30, 2021

Abivax publishes Universal Registration Document 2021 “Document d’Enregistrement Universel”

April 19, 2021

Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis

April 14, 2021

Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis

March 31, 2021

Abivax reports 2020 financial results and operations update

March 05, 2021

Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy